Among the most promising agents in this respect are the glucagon‐like 1 receptor (GLP‐1R) agonists that have been extensively studied in obesity and T2DM and induce both weight loss and improved glycaemic control.243. This evidence concerns the gene GLP1R and obesity disorder.